|
注册号: Registration number: |
ChiCTR2500095489 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-08 09:51:34 |
|
注册时间: Date of Registration: |
2025-01-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
自稳定型腰椎融合器临床试验 |
|
Public title: |
Clinical Trial of Uni-L Standalone Lumbar Interbody Fusion Cage |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
自稳定型腰椎融合器临床试验 |
|
Scientific title: |
Clinical Trial of Uni-L Standalone Lumbar Interbody Fusion Cage |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
任博文 |
研究负责人: |
毛克亚 |
|
Applicant: |
Bowen Ren |
Study leader: |
Keya Mao |
|
申请注册联系人电话: Applicant telephone: |
+86 185 0124 7321 |
研究负责人电话:
Study leader's |
+86 10 6693 8402 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
docrenbowen@163.com |
研究负责人电子邮件: Study leader's E-mail: |
maokeya@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
No. 28 Fuxing road, Haidian district, Beijing |
Study leader's address: |
No. 28 Fuxing road, Haidian district, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100853 |
研究负责人邮政编码: Study leader's postcode: |
100853 |
|
申请人所在单位: |
中国人民解放军总医院 |
||
|
Applicant's institution: |
General Hospital of the Chinese people's Liberation Army |
||
|
研究负责人所在单位: |
中国人民解放军总医院 |
||
|
Affiliation of the Leader: |
General Hospital of the Chinese people's Liberation Army |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审第S2024-659-01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Chinese PLA General Hosptial |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-31 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
No. 28 Fuxing road, Haidian district, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
General Hospital of the Chinese people's Liberation Army |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China |
||||||||||||||||||||||
|
研究疾病: |
需腰椎侧入路手术的疾病 |
||||||||||||||||||||||
|
Target disease: |
Diseases requiring lumbar lateral approach surgery |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过上市后临床试验考察自稳定型腰椎融合器在广泛使用条件下的疗效和不良反应,进一步评估产品在扩大人群中使用的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the efficacy and adverse reactions of Uni-L Standalone Lumbar Interbody Fusion Cage under widespread use conditions through post-market clinical trials, and further evaluate the safety and effectiveness of the product in the expanding population. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)明显的局部或全身严重感染; (2)可能导致术后护理期间出现难以接受的固定失败或并发症风险的任何精神或神经肌肉及血管疾患; (3)妊娠; (4)明确的或怀疑对产品所用金属、高分子材料或对异物过敏; (5)严重骨质疏松症,经临床判定不适宜手术者; (6)系统性或代谢性疾病; (7)患者精神上无能力或者不能理解参与研究的要求; (8)脊柱肿瘤,包括转移瘤; (9)研究者认为不宜参加研究的。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Severe systemic or local infection; (2) Any psychiatric or neuromuscular disorders that may result in an unacceptable risk of fixation failure or complications during postoperative care; (3) Pregnancy; (4) Clear or suspected allergy to metals, polymer materials, or foreign objects used in the product; (5) Patients with severe osteoporosis who are clinically deemed unsuitable for surgery; (6) Systemic or metabolic diseases; (7) The patient is incapable or unable to understand the requirements for participating research mentally; (8) Spinal tumors, including metastases; (9) Patients whom the investigators deemed inappropriate to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-31 00:00:00至 To 2026-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-13 00:00:00 至 To 2026-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
入组受试者通过统计学专业人员提供的随机系统方式按1:1随机分配到试验组和对照组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Enrolled subjects were randomly assigned to the treatment and control groups on a 1:1 basis by random system |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集采用病历记录表形式,数据记录于Fozo智能随访系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is in the form of CRF and Data recorded in Fozo intelligent follow-up system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |